Zobrazeno 1 - 10
of 32
pro vyhledávání: ''
Autor:
Agatha Lyczek, Aziz M Rangwala, YiTing Paung, Jessica Tom, John D. Chodera, Markus A. Seeliger, Matthew B. Robers, Stefan Knapp, Jiaye Guo, Hannah Philipose, Benedict-Tilman Berger, Steven K. Albanese
Protein kinase inhibitors are potent anti-cancer therapeutics (1). For example, the Bcr-Abl kinase inhibitor imatinib decreases mortality for Chronic Myeloid Leukemia (CML) by 80% (2, 3), but 22-41% of patients acquire resistance to imatinib (4). Abo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd69ca677774e14b1401b47658688b79
https://doi.org/10.1101/2021.06.28.449968
https://doi.org/10.1101/2021.06.28.449968
Autor:
Klamova H, Brezinova J, Obr A, Ransdorfova S, Cermakova K, Zackova M, Machackova-Lopotova T, Mitrovsky O, Myslivcova D
Chronic myelogenous leukemia (CML) is a myeloproliferative disease characterized by the presence of a BCR-ABL oncogene. Despite the high performance of treatment with tyrosine kinase inhibitors (TKI), about 30 % of patients develop resistance to ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35f830a49f90e4732f0a20452a3fc024
https://doi.org/10.1101/2021.06.28.450156
https://doi.org/10.1101/2021.06.28.450156
Genotoxic agents remain the mainstay of cancer treatment. Unfortunately, the clinical benefits are often countered by a rapid tumor adaptive response. Here, we report that the oncoprotein B cell lymphoma 6 (BCL6) is a core component that confers tumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cad59f3dcabc854b0b59fd4b6a162cef
https://doi.org/10.1101/2021.06.15.448559
https://doi.org/10.1101/2021.06.15.448559
Autor:
Sergej Erschow, Matthias Eder, Michaela Scherr, Hanna Kirchhoff, Robert Zweigerdt, Karsli U, Arnold Ganser, Melanie Ricke-Hoch, Denise Hilfiker-Kleiner, Katharina Wohlan, Stefan Pietzsch
Targeted therapies are currently considered the best cost-benefit anti-cancer treatment. In hematological malignancies, however, relapse rates and non-hematopoietic side effects including cardiotoxicity remain high. We here describe significant heart
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::84413874171387c56f5eae07d5582fe3
https://doi.org/10.1101/2021.06.04.447070
https://doi.org/10.1101/2021.06.04.447070
Autor:
Magdalena Wolczyk, Marta Brewińska-Olchowik, Katarzyna Piwocka, Julian Swatler, Ilona Seferynska, Shamba S Mondal, Monika Kusio-Kobialka, Agata Klejman, Laura Turos-Korgul, Wioleta Dudka, Milena Wiech, Marcin M Machnicki, Agata Kominek, Tomasz Stoklosa, Grazyna Hoser
Integrated Stress Response (ISR) facilitates cellular adaptation to variable environmental conditions by reprogramming cellular response. Activation of ISR was reported in neurological disorders and solid tumours, but its function in hematological ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbf964183c5f1140867d70fb88e4536d
https://doi.org/10.1101/2021.05.05.442756
https://doi.org/10.1101/2021.05.05.442756
Autor:
Fangfei Zhang, Kexin Liu, Gan L, Weigang Ge, Yi Zhu, Yaoting Sun, William J. Liu, Tiannan Guo
Drug resistance is a critical obstacle to effective treatment in patients with chronic myeloid leukemia (CML). To understand the underlying resistance mechanisms in response to imatinib (IMA) and adriamycin (ADR), the parental K562 cells were treated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2cc88002e801526f865e2d8f39fbc50f
https://doi.org/10.1101/2021.04.08.438976
https://doi.org/10.1101/2021.04.08.438976
Autor:
Barbara Saxty, Joseph Inns, Helen J. Blair, José Luis Marín-Rubio, Olaf Heidenreich, Tiaan Heunis, Jonathan M. Scott, Matthias Trost, James M. Allan, Maria Emilia Dueñas, Rachel E. Heap, A. John Simpson
Inflammatory responses are important in cancer, particularly in the context of monocyte-rich aggressive myeloid neoplasm. We developed a label-free cellular phenotypic drug discovery assay to identify anti-inflammatory drugs in human monocytes derive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3adb2e023d75a4eae3fe888fad555ad
https://doi.org/10.1101/2021.03.29.437557
https://doi.org/10.1101/2021.03.29.437557
Autor:
Christian Hurtz, Lai N. Chan, Scott A. Armstrong, Jianjun Chen, Erica Ballabio, Huimin Geng, Thomas A. Milne, Gauri Deb, Patricia Ernst, Ari Melnick, Haytham Khoury, Chun-Wei Chen, Gang Xiao, Markus Müschen
Publikováno v:
Genes & Development. 33:1265-1279
Chromosomal rearrangements of the mixed lineage leukemia (MLL) gene occur in ∼10% of B-cell acute lymphoblastic leukemia (B-ALL) and define a group of patients with dismal outcomes. Immunohistochemical staining of bone marrow biopsies from most of
Autor:
Spartaco Santi, Mattia Lauriola, Valerio Gelfo, Michelangelo Fiorentino, Gabriele D'Uva, Donatella Romaniello, Balazs Gyorffy, Martina Mazzeschi, Michela Sgarzi, Ruth H. Palmer, Carola Cavallo
In the last years, several efforts have been made to classify colorectal cancer (CRC) into well-defined molecular subgroups, representing the intrinsic inter-patient heterogeneity, known as Consensus Molecular Subtypes (CMSs). In this work, we perfor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dde604a6aa38bc897e123c464410415a
https://doi.org/10.1101/2020.10.07.307991
https://doi.org/10.1101/2020.10.07.307991
Autor:
Bruno Quesnel, Béatrice Turcq, Didier Bouscary, Raeeka Khamari, Salim Dekiouk, Jerome Kluza, Nicolas Germain, Francois-Xavier Mahon, Quentin Fovez, Patrice Maboudou, William Laine, Valérie Coiteux, Philippe Marchetti, Marie Joncquel, Thierry Idziorek, Bart Ghesquière, Anne Trinh
Long-term treatment with tyrosine kinase inhibitors (TKI) represents an effective treatment for chronic myeloid leukemia (CML) and discontinuation of TKI therapy is now proposed to patient with deep molecular responses. However, evidence demonstratin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5925202479711cc8a5629bc5150cc0bf
https://doi.org/10.1101/2020.09.21.305714
https://doi.org/10.1101/2020.09.21.305714